17:01 , Jan 31, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor levels of RPS6KA5 could help predict survival in ESR1-positive breast cancer. In 193 patients, low primary tumor levels of RPS6KA5 mRNA were associated with poor metastasis-free survival. In another 214 patients,...
07:00 , Jun 27, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Ataxia Ribosomal protein S6 kinase 90 kDa polypeptide 5 (RPS6KA5; MSK1); ataxin 1 (ATXN1) Fly and mouse studies suggest inhibiting MSK1...
07:00 , Jul 1, 2002 |  BC Week In Review  |  Company News

Molecular Devices sales and marketing update

Molecular Devices Corp. (MDCC), Sunnyvale, Calif.   Business: High throughput screening   MDCC launched six assay kits for use with its IMAP kinase inhibitor screening technology: PRAK , MSK1 ; Src , Fyn, Lck and...